Kala Bio Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • KALA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.73
  • (As of Friday Closing)

Kala Bio General Information

Description

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Contact Information

Website
www.kalarx.com
Formerly Known As
Hanes Newco, Kala Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1167 Massachusetts Avenue
  • Arlington, MA 02476
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 1167 Massachusetts Avenue
  • Arlington, MA 02476
  • United States
+1 (781)

Kala Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kala Bio Stock Performance

As of 20-Nov-2026, Kala Bio’s stock price is $2.73. Its current market cap is $1.76M with 645K shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.73 $3.04 $2.65 - $2.86K $1.76M 645K 51.8K -$321.30

Kala Bio Financials Summary

As of 30-Jun-2026, Kala Bio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 23,397 21,771 20,805 (1,134)
Revenue 0 0 0 0
EBITDA (9,278) (24,527) (34,525) (38,793)
Net Income (10,080) (26,980) (38,511) (42,199)
Total Assets 10,582 9,490 55,483 55,949
Total Debt 0 0 32,252 36,323
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kala Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kala Bio‘s full profile, request access.

Request a free trial

Kala Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kala Bio‘s full profile, request access.

Request a free trial

Kala Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization
Drug Discovery
Arlington, MA
6 As of 2026

Lexington, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kala Bio Competitors (25)

One of Kala Bio’s 25 competitors is Aldeyra Therapeutics, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 25 competitors. Get the full list »

Kala Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kala Bio Acquisitions (1)

Kala Bio’s most recent deal was a Merger/Acquisition with Combangio for . The deal was made on 15-Nov-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Combangio 15-Nov-2021 Merger/Acquisition Drug Discovery
To view Kala Bio’s complete acquisitions history, request access »

Kala Bio ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.72 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Kala Bio’s complete esg history, request access »

Kala Bio FAQs

  • When was Kala Bio founded?

    Kala Bio was founded in 2009.

  • Where is Kala Bio headquartered?

    Kala Bio is headquartered in Arlington, MA.

  • What is the size of Kala Bio?

    Kala Bio has 6 total employees.

  • What industry is Kala Bio in?

    Kala Bio’s primary industry is Drug Discovery.

  • Is Kala Bio a private or public company?

    Kala Bio is a Public company.

  • What is Kala Bio’s stock symbol?

    The ticker symbol for Kala Bio is KALA.

  • What is the current stock price of Kala Bio?

    As of 20-Nov-2026 the stock price of Kala Bio is $2.73.

  • What is the current market cap of Kala Bio?

    The current market capitalization of Kala Bio is $1.76M.

  • Who are Kala Bio’s competitors?

    Aldeyra Therapeutics, Sarepta Therapeutics, Sangamo Therapeutics, ONL Therapeutics, and Foventa Therapeutics are some of the 25 competitors of Kala Bio.

  • What is Kala Bio’s annual earnings per share (EPS)?

    Kala Bio’s EPS for 12 months was -$321.30.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process